Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Nikolaos Trikalinos (NPI 1790947224)

Field	Value
Entity Type	Individual
Organization	Nikolaos Trikalinos
Address	4921 Parkview Pl
City	Saint Louis
State	MO
ZIP	63110
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 26, 2008

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

NIKOLAOS TRIKALINOS is a Medical Oncology Physician in SAINT LOUIS, MO with lifetime Medicare revenue of $1.6M and Medicaid revenue: none (no Medicaid billing on file). The provider’s NPI was enumerated on 2008-06-26 (~18 years ago), indicating long-standing participation in Medicare programs.

Revenue is highly concentrated in three injectable therapy codes: J9271 accounts for $576.2K (35.9% of this provider's total Medicare revenue), J2353 accounts for $476.3K (29.7%), and J9144 accounts for $396.7K (24.7%). Together these top three codes represent 90.3% of this provider's total Medicare revenue, signaling a narrowly focused revenue base tied to specific oncology agents.

The code mix points to an infusion- and drug-delivery–centric oncology practice rather than a high-volume office visit model: high-revenue J-codes for pembrolizumab, octreotide depot, and daratumumab dominate, while evaluation-and-management revenue is modest (99214: $19.6K, 200 claims, 1.2%). Chemotherapy administration codes (e.g., 96413: $41.2K, 408 claims) appear but contribute far less than the J-code drug revenues, suggesting operations emphasize procurement and administration of specialty injectables.

Competitive standing is mixed by code: for J2353 this provider ranks #1 of 18 providers nationally (100th percentile; notably above typical national volume), marking them as a dominant outlier for octreotide depot. By contrast, J9271 ranks #806 of 1841 (55th percentile; typical, unremarkable volume) and J9144 ranks #191 of 615 (67th percentile; typical, unremarkable volume), indicating moderate participation on those agents relative to national peers.

Claim volumes and per-claim payments differ materially across the top agents: J9271 shows 13.4K claims at $43 avg paid/claim, J9144 shows 10.4K claims at $38 avg paid/claim, and J2353 shows 2.9K claims at $162 avg paid/claim. This pattern suggests revenue drivers include both high unit counts for some agents and higher per-unit reimbursement for others, so supply-chain and inventory management for high-volume, lower-unit-price agents is likely important to operations.

The provider is effectively single-payer with respect to public programs—Medicare accounts for the documented public revenue stream while Medicaid is absent—which creates payer-concentration exposure if commercial or Medicaid volumes shift or if Medicare reimbursement policies change. Analysts and payers should treat this profile as Medicare-centric when assessing utilization risk and network value.

Tenure and stability are supported by the long NPI history (2008-06-26, ~18 years ago) combined with sustained high-volume J-code activity, which together suggest an established infusion practice with operational experience managing specialty oncology therapies. This longevity may reflect stable referral relationships or clinic infrastructure needed to support repeated injectable therapy administration.

Ancillary-service footprint is limited in billed E/M revenue and procedural diagnostics: small contributions from office visits (99214: $19.6K) and bone marrow biopsy (38222: $2.9K) imply that the office’s clinical workflow prioritizes infusion sessions and drug administration logistics over high-frequency diagnostic or consultative visits. For payers evaluating network capacity, the provider appears to function primarily as an infusion/drug-administration node rather than a broad outpatient oncology clinic.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

39 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,400	$40	$576.2K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	2,940	$160	$476.3K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	10,440	$40	$396.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	410	$100	$41.2K
J0897	Injection, denosumab, 1 mg	1,620	$20	$29.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	200	$100	$19.6K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	60	$130	$7.6K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	110	$60	$6.2K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	50	$130	$6K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	240	$20	$5.6K

Showing 1–10 of 39

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 39 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Nikolaos Trikalinos — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

39 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	40	9,100	$40	$502K
J9144	6	20	7,200	$40	$308.4K
J2353	1	10	1,100	$160	$225.3K
J0897	140	210	2,400	$20	$82.4K
96413	24	160	140	$100	$19.1K
J9217	64	70	100	$130	$17.7K
J3490	18	80	40	$150	$14K
99214	2,678	8,960	100	$80	$13.9K
99213	7,261	8,730	70	$50	$7K
G0498	8	40	40	$130	$6.1K

Showing 1–10 of 39

Related Providers

Other providers that share a Tax Identification Number (TIN) with Nikolaos Trikalinos, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Washington University	MO	Multi-Specialty Clinic/Center	$0	$22M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$14.8M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$10.4M
Washington University	MO	Emergency Care Clinic/Center	$0	$9.1M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$6.9M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$4.4M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$4M
John Visconti	IL	Medical Oncology Physician	$2.8M	$149.1K
Deepnarayan Tiwarri	MD	Hematology & Oncology Physician	$2.6M	$0
Peter Oppelt	MO	Medical Oncology Physician	$2.5M	$15.8K

Nearby Providers

Other providers in the same ZIP code as Nikolaos Trikalinos, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Council For Extended Care	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$98.1M
St. Louis Children's Hospital	MO	Children's Hospital	$0	$66.9M
Barnes Jewish Hospital	MO	General Acute Care Hospital	$0	$61.4M
Paraquad Inc	MO	Customized Equipment (DME)	$0	$56.3M
Cooperative Home Care, Inc.	MO	Home Health Agency	$0	$20.6M
New Beginnings In Home Services, LLC	MO	In Home Supportive Care Agency	$0	$11.6M
Bjc Home Care Services	MO	Durable Medical Equipment & Medical Supplies	$0	$8.2M
Wallace Family In Home Health LLC	MO	In Home Supportive Care Agency	$0	$6.6M
Cooperative Home Care	MO	Home Health Agency	$0	$5.5M
Josephines Caring Hands	MO	In Home Supportive Care Agency	$0	$3.4M

Nikolaos Trikalinos — Billing Profile & Reimbursement Data

Sign up for Nikolaos Trikalinos — Billing Profile & Reimbursement Data policy alerts

Nikolaos Trikalinos — Billing Profile & Reimbursement Data

Sign up for Nikolaos Trikalinos — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References